ALDOB Promotes Neuroblastoma Metastasis by Affecting EMT Pathway and is a Potential Prognostic Factor

Background： Aldolase B (ALDOB) is a member of the aldolase family, which is the fourth enzyme in glycolysis process. In recent years, the non-enzymatic effects of some glycolytic enzymes have been reported to promote the formation of several human tumors, but the non-enzymatic action of ALDOB in neuroblastoma(NB) remains unclear. This study aims to explore the non-enzymatic effect of ALDOB in neuroblastoma.Methods： We used immunohistochemistry to examine 63 patients tissue microarray samples and 3 pairs of lymph node metastases and the primary tissue samples, and evaluated the relationship between ALDOB expression level and clinical characteristics. We then analyzed the public datasets of NB based on microarray to verify the immunohistochemistry results. In addition, we conducted in vitro experiments on SK-N-BE(2) and SH-SY5Y cell lines to explore the molecular mechanism.Results： Immunohistochemistry indicated ALDOB is significantly associated with INSS stage and tumor metastasis in NB, public dataset analysis showed ALDOB is related to NB patient survival remarkably. In vitro experiments displayed silencing ALDOB may inhibit the cell migration by epithelial-mesenchymal transition (EMT) pathway.Conclusions： Our finding demonstrated that ALDOB can affect the metastasis of NB by EMT pathway and may be a potential target for neuroblastoma therapy in the future.